Program
povetacicept
Also written as “Povetacicept” and “ALPN-303”.
Its studies are mostly in Glomerulonephritis, IGA · Glomerulonephritis, Membranous · Myasthenia Gravis · Lupus Nephritis · Purpura, Thrombocytopenic, Idiopathic, led by Vertex Pharmaceuticals.
Furthest: phase 3, since Aug 19, 20249 company-led studies, 6 open or runningNext primary completion: Dec 12, 2027 (phase 3)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Vertex Pharmaceuticals | 96 open or running | phase 3since Aug 19, 2024 | Aug 26, 2021 | Dec 12, 2027phase 3 · NCT07890909 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Aug 26, 2021First study: phase 1 study in Healthy VolunteersFirst studyNCT05034484 · 72 enrolled · Australia
- Feb 8, 20232 phase 2 studiesNCT05732402, NCT05757570
- Aug 19, 2024Phase 3 study in Glomerulonephritis, IGANCT06564142 · 605 enrolled · United States, Australia, Austria and more
- May 30, 2025Phase 1 study in Healthy VolunteersNCT07010406 · 136 enrolled · United States
- Sep 24, 2025Phase 3 study in Primary Membranous NephropathyNCT07204275 · 176 planned · United States, Australia, Brazil and more
- Mar 24, 2026Phase 2 study in Myasthenia GravisNCT07501702 · 34 enrolled · United States, Australia, Poland and more
- Aug 20, 2026Phase 3 study in Glomerulonephritis, IGANCT07807995 · 605 planned · United States
- Oct 15, 2026Phase 3 study in Glomerulonephritis, IGANCT07890909 · 40 planned
Ahead
- Dec 12, 2027Primary completion: phase 3 study in Glomerulonephritis, IGANCT07890909
- Jan 30, 2028Primary completion: phase 3 study in Glomerulonephritis, IGANCT06564142
- Mar 2, 2028Primary completion: phase 2 study in Lupus NephritisNCT05732402
- Dec 29, 2028Primary completion: phase 3 study in Primary Membranous NephropathyNCT07204275
TargetBeta
TNFRSF13B →read by rule
“An affinity-optimized Fc fusion protein composed of an engineered variant domain of human tumor necrosis factor receptor superfamily member 13B (TNFRSF13B; TNF receptor superfamily 13B; transmembrane activator and CAML interactor; transmembrane activator and calcium modulator and cyclophilin ligand ”NCIt, by rule
Other programs on TNFRSF13B
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| telitaciceptrule | RemeGen | phase 3 | 25 |
| SHR-2173 | Jiangsu HengRui Medicine | phase 2 | 8 |
Studies
All 9 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07890909Glomerulonephritis, IGA | 3 | Not yet recruiting | Dec 12, 2027 | 40 |
| NCT07807995Glomerulonephritis, IGA · United States | 3 | By invitation | Dec 28, 2029 | 605 |
| NCT07501702Myasthenia Gravis · United States, Australia, Poland and more | 2 | Active, not recruiting | Mar 2, 2029 | 34 |
| NCT07204275Primary Membranous Nephropathy · United States, Australia, Brazil and more | 3 | Recruiting | Dec 29, 2028 | 176 |
| NCT07010406Healthy Volunteers · United States | 1 | Completed | Aug 19, 2025 | 136 |
| NCT06564142Glomerulonephritis, IGA · United States, Australia, Austria and more | 3 | Active, not recruiting | Jan 30, 2028 | 605 |
| NCT05757570Purpura, Thrombocytopenic, Idiopathic · United States, Australia, Austria and more | 2 | Completed | Aug 12, 2026 | 30 |
| NCT05732402Lupus Nephritis · United States, Australia, Puerto Rico and more | 2 | Active, not recruiting | Mar 2, 2028 | 72 |
| NCT05034484Healthy Volunteers · Australia | 1 | Completed | Feb 27, 2023 | 72 |
How it is read
Names in the registry
- “Povetacicept”, 8 entries
- “ALPN-303”, 1 entry
Conditions, from the studies’ own filings
- Glomerulonephritis, IGA, 3 studies
- Glomerulonephritis, Membranous, 1 study
- Myasthenia Gravis, 1 study
- Lupus Nephritis, 1 study
- Purpura, Thrombocytopenic, Idiopathic, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.